Munich Re, Marsh Seeking ‘Next Blockbuster’ With Pharma Coverage
This article is for subscribers only.
Munich Re and Marsh & McLennan Cos., the largest insurance broker by market value, introduced a product to insure U.S. pharmaceutical companies against regulatory actions that could cause them to suspend manufacturing.
The product would cover as much as $10 million in non-damage business-interruption costs tied to violations of federal manufacturing standards, Munich Re said Wednesday in a statement. The Munich-based company is the world’s biggest reinsurer.